Should I hold Coumadin (warfarin) when the international normalized ratio (INR) is 3.2 and there is no active bleeding?

Do Not Hold Coumadin for INR 3.2 Without Active Bleeding

For a patient with INR 3.2 and no active bleeding, you should continue the current warfarin dose without holding it, and recheck the INR in 1-2 weeks. 1

Rationale Based on Guidelines

The 2012 CHEST guidelines specifically address this scenario. For patients with previously stable therapeutic INRs who present with a single out-of-range INR of 0.5 below or above therapeutic range, the recommendation is to continue the current dose and test the INR within 1-2 weeks 1.

An INR of 3.2 falls exactly into this category:

• If your target range is 2.0-3.0, the INR is only 0.2 above the upper limit
• This represents a minor, isolated elevation
• No dose adjustment is needed

Supporting Evidence

The guideline recommendation is based on two key studies 1:

1. Randomized controlled trial: Compared one-time dose adjustments versus continuing the same dose for INRs between 1.5-4.4. Results showed no difference in therapeutic INR achievement at 2-week follow-up (44% vs 40% out of range, p=0.75)

2. Observational study: Specifically evaluated INRs of 3.2-3.4 in patients with target range 2.0-3.0. When the dose was continued (78% of the time in anticoagulation management services), 63% achieved therapeutic INR at follow-up with no major bleeding or thromboembolic events during 14-30 days 1

Risk Assessment

The FDA label notes that bleeding risk increases when INR exceeds 3.0, particularly for intracranial hemorrhage when INR >3.5 2. However, at 3.2:

• You are well below the high-risk threshold of 3.5
• The 2018 CHEST guideline confirms bleeding risk increases substantially when INR >3.5, not at 3.2 3
• Without active bleeding, the immediate risk is minimal

Clinical Algorithm

For INR 3.2 with no bleeding:

1. Continue current warfarin dose unchanged
2. Recheck INR in 1-2 weeks 1
3. Assess for factors causing INR drift (dietary changes, new medications, illness)
4. If next INR remains elevated or continues rising, then consider dose reduction

Do NOT:

• Hold warfarin doses
• Give vitamin K (reserved for INR >4.5-5.0 without bleeding) 4, 5
• Make one-time "booster" or reduced doses

Important Caveats

Consider holding or reducing dose if:

• Patient has high bleeding risk factors (age ≥75, history of GI bleeding, recent trauma, malignancy, renal impairment) 2
• Upcoming invasive procedure within days
• INR trend shows progressive rise over multiple measurements
• Patient has mechanical mitral valve (target 2.5-3.5), where 3.2 is actually therapeutic 6

The key principle: A single mildly elevated INR does not require intervention. Overreacting with dose holds or reductions often leads to subtherapeutic anticoagulation and increased thrombotic risk 1, 7.